ArticleIJU case reports2026
A Rare Case of Suspected Immune-Related Encephalopathy Following Pembrolizumab Plus Lenvatinib Therapy for Renal Cell Carcinoma.
Article in IJU case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Immune-related encephalopathy is a rare neurological adverse event associated with immune checkpoint inhibitors. Neuroimaging and cerebrospinal fluid findings are often unremarkable, making the diagnosis challenging. Case Presentation: A 70-year-old man with advanced clear cell renal cell carcinoma (RCC) was considered unresectable because of suspected adjacent organ invasion and high surgical risk. Therefore, pembrolizumab plus lenvatinib therapy was initiated, but 6 days later, he developed confusion, speech difficulty, and gait disturbance. Blood tests, whole-body computed tomography (CT), contrast-enhanced brain CT, contrast-enhanced brain magnetic resonance imaging (MRI), electroencephalography, and cerebrospinal fluid examination showed no significant abnormalities. After excluding other causes, grade 3 immune-related encephalopathy was suspected. Pembrolizumab and Lenvatinib were discontinued and high-dose corticosteroids were started, leading to subsequent neurological improvement without residual deficits. Conclusion: Immune-related encephalopathy may occur early after pembrolizumab therapy. Early recognition and prompt steroid treatment are essential for a favorable neurological recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.